التفاصيل البيبلوغرافية
| العنوان: |
Adjunctive Antiplatelet Treatment in Primary Percutaneous Coronary Intervention |
| المؤلفون: |
Perperis, Angelos, Galati, Anastasia, Alexopoulos, Dimitrios |
| المصدر: |
Hospital Chronicles; Vol. 7 No. 1 (2012); 39-48 ; 1792-9172 ; 1790-7306 |
| بيانات النشر: |
Hospital Chronicles |
| سنة النشر: |
2011 |
| المجموعة: |
Hospital Chronicles (E-Journal) |
| مصطلحات موضوعية: |
clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, abciximab, tirofiban, eptifibatide, antiplatelet treatment, ST elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PCI) |
| الوصف: |
Background: Despite significant advances in the management of coronary heart disease, myocardial infarction is still associated with high mortality. Thienopyridines and glycoprotein IIb/IIIa inhibitors have been used extensively in the management of ST segment elevation myocardial infarction. Objective: This article discusses the evidence from clinical trials and registries concerning the benefits of thienopyridines, reviews the results of published multicenter, randomized controlled trials of the efficacy and safety of platelet GPIIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention (PCI) and presents the recent guidelines.Methods: Data for this review were identified by broad searches of MEDLINE, Current Contents and references from relevant articles (1980-2011); numerous articles were identified through searches of the extensive files of the authors and selected based on their importance, oppurtunity for further reading and up to date information. Search terms included thienopyridines, platelet aggregation inhibitors, percutaneous coronary intervention, antiplatelet therapy, ST elevation myocardial infarction (STEMI), primary percutaneous coronary intervention. Only English language papers were reviewed. No restrictions were set on the type of papers.Results: Clopidogrel is the most commonly used thienopyridine in patients undergoing primary PCI. Recently new inhibitors of P2Y12 receptors, like prasugrel and ticagrelor, have become available, which have a more potent and rapid onset of action, with similar safety profile, which is specifically targeted to the subgroup of primary PCI. On the other hand, the platelet glycoprotein IIb/IIIa inhibitors have aided and abetted medical management of acute coronary syndromes and proved an important adjunctive therapy in percutaneous coronary interventions. Platelet glycoprotein IIb/IIIa inhibitors, although not recommended for routine therapy, have an important role at the time of primary PCI, ... |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| Relation: |
http://www.hospitalchronicles.gr/index.php/hchr/article/view/412/408; http://www.hospitalchronicles.gr/index.php/hchr/article/view/412 |
| الاتاحة: |
http://www.hospitalchronicles.gr/index.php/hchr/article/view/412 |
| رقم الانضمام: |
edsbas.EF173F61 |
| قاعدة البيانات: |
BASE |